QURE News

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of uniQure N.V. (QURE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Pomerantz LLP Advises Investors of Class Action Against uniQure N.V. – QURE

QURE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

UNIQURE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against uniQure N.V. and Encourages Investors to Contact the Firm

uniQure N.V. (QURE) Investors: Kessler Topaz Meltzer & Check, LLP Announces That the Firm Has Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. and Encourages Investors to Contact the Firm

QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease